Feifei Na, PhD
Assistant Research Fellow, West China School of Medicine, Sichuan University.
Education
- BS, Clinical Medicine (Eight-Year Program), West China School of Medicine, Sichuan University (2006.09–2011.07)
- PhD, Clinical Medicine (Eight-Year Program), West China School of Medicine, Sichuan University (2011.09–2014.06). Supervisor: You Lu
- Postdoc, West China School of Medicine, Sichuan University (2014.07–2017.12). Supervisors: Yuquan Wei and Chong Chen
Working Experience
- Assistant Research Fellow, West China School of Medicine, Sichuan University (2014.07–2017.12)
- Attending Physician, Department of Thoracic Oncology, West China Hospital, Sichuan University (2018.01–2023.09)
- Associate Professor / Associate Chief Physician, Department of Thoracic Oncology, West China Hospital, Sichuan University (2023.09–present)
- Rotating Program Director, Department of Health Sciences, National Natural Science Foundation of China (2026.03–present)
Selected Publications
- Na F#, Pan X#, Chen J, Chen X, Wang M, Chi P, et al. KMT2C loss promotes small cell lung cancer metastasis through DNMT3A-mediated epigenetic reprogramming. Nature Cancer. 2022 Jun;3(6):753-767.
- Wang Y#, Zhong A#, Wang B#, Zhai X, Lei C, Liang Z, Deng X, Zhong J, Xiao C, Zheng J, Wu B, Zhang L, Wang Y, Luo X, Wang J, Zhang M, Liu H, Wan X, Dai S, Yang Y, Zhang S, Wang W, Yang S, Xue J, Zhao C, Tammela T, Li Z, Zhang Y*, Na F*, Wang M*, Liu Y*, Chen C*. A blood-brain barrier-like vascular gate limits immunotherapy efficacy in neuroendocrine cancers. Cell. 2026 Jun 25; doi: 10.1016/j.cell.2026.04.017. Epub 2026 May 7.
- Wang H, Yao Z, Kang K, Zhou L, Xiu W, Sun J, Xie C, Yu M, Li Y, Zhang Y, Zheng Y, Pan X, Wu Y, Luo R, Lin G, Wang L, Tang M, Liao S, Zhu J, Zhou X, Zhang X, Xu Y, Liu Y, Peng F, Wang J, Xiang L, Yin L, Deng L, Huang M, Gong Y, Zou B, Wang H, Wu L, Yuan Z, Bi N, Fan M, Xu Y, Tong R, Yi L, Gan L, Xue J, Mo X, Chen C, Na F*, Lu Y*. Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer. Med. 2024 Oct 11;5(10):1237-1254.e9.
- Wang M, Wang Y, Pan X, Wang B, Wang Y, Luo X, Deng X, Liu L, Chen X, Zhai X, Wu B, Zhang Q, Ren Y, Li J, Li X, Cao F, Yang Y, Deng X, Li R, Lu Z, Tan P, Chen J, Li Y, Liu Y, Liu J, Wang Y, Deng H, Su Z, Wang W, Wang Y, Yang Y, Zhao C, Xue J, Wei Y, Zhang K*, Na F*, Liu Y*, Chen C*. Acquired resistance to immunotherapy by physical barriers with cancer cell-expressing collagens in non-small cell lung cancer. Proc Natl Acad Sci USA. 2025 Jun 17;122(24):e2500019122.
- Zhang M, Zhong A, Liu H, Zhao L, Wang Y, Lu Z, Zhang L, Pan X, Liang Z, Gao L, Chen X, Wang J, Dai S, Wan X, Wang M, Chen J, Du J, Chen S, Peng T, Cai J, Chen L, Yang Y, Xiao C, Yao M, Xu J, Qin R, Yang C, Wu B, Zhang Q, Liu S, Zhao C, Deng H, Wang Y, Chen L, Hu J, Hu B, Yang S, Na F*, Guo L*, Liu Y*, Chen C*. EZH2 loss promotes gastric squamous cell carcinoma. Nature Communications. 2025 Jul 1;16(1):6032.
- Wang J, Du J, Luo X, Guo L, Liu Y, Zhou J, Zou Y, Lu Z, Pan X, Chen X, Zhong A, Wan X, Wang L, Liu H, Dai S, Zhang S, Xiong X, Tan P, Wang M, Wu B, Zhang Q, Wang Y, Zhang M, Lu R, Lin H, Li Y, Li Y, Han Z, Chen L, Hu B*, Liu Y*, Na F*, Chen C*. A platform of functional studies of ESCC-associated gene mutations identifies the roles of TGFBR2 in ESCC progression and metastasis. Cell Reports. 2024 Nov 26;43(11):114952.
- Feng B, Zheng Y, Zhang J, Tang M, Na F*. Chemoimmunotherapy combined with consolidative thoracic radiotherapy for extensive-stage small cell lung cancer: A systematic review and meta-analysis. Radiotherapy and Oncology. 2024 Jan;190:110014.
- Chen J, Dai S, Zhao L, Peng Y, Sun C, Peng H, Zhong Q, Quan Y, Li Y, Chen X, Pan X, Zhong A, Wang M, Zhang M, Yang S, Lu Y, Lian Z, Liu Y, Zhou S, Li Z, Na F*, Chen C*. A new type of endometrial cancer models in mice revealing the functional roles of genetic drivers and exploring their susceptibilities. Advanced Science. 2023 Aug;10(24):e2300383.
- Chen J, Zhao L, Peng H, Dai S, Quan Y, Wang M, Wang J, Bi Z, Zheng Y, Zhou S, Liu Y, Chen C*, Na F*. An organoid-based drug screening identified a menin-MLL inhibitor for endometrial cancer through regulating the HIF pathway. Cancer Gene Therapy. 2021 Feb;28(1-2):112-125.
- Pan X#, Wang J#, Guo L#, Na F#, et al. Identifying a confused cell identity for esophageal squamous cell carcinoma. Signal Transduction and Targeted Therapy. 2022 Apr 13;7(1):122.
# Equal contribution; * Corresponding author.